Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 2/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20298607 | 1.00 | ATIC (0.40) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL29140827 | 0.83 | — | — | |
| SCHEMBL29152304 | 0.81 | ATIC (0.47) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL22684942 | 0.79 | ATIC (0.65) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL938225 | 0.78 | ATIC (0.60) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL28773388 | 0.78 | ATIC (0.47) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL940486 | 0.77 | ATIC (0.64) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL850150 | 0.72 | FBP1 (0.49) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL2509891 | 0.68 | ATIC (0.46) | ATICFBP1KDM4ETDP1ALDH1A1 | |
| SCHEMBL4307801 | 0.66 | KDM4E (0.56) | ATICFBP1KDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3989992-A2 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | Holobiome, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2020264390-A2 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | HOLOBIOME, INC. (US) | 2020-12-30 | — | — | WO | claimed |
| US-8494779-B2 | Method for screening essential metabolites in growth of microorganisms | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | claimed |
| US-20250368691-A1 | Virulence Attenuated Bacteria Based Protein Delivery | UNIV BASEL (CH) | 2025-12-04 | — | — | US | disclosed |
| US-20250262254-A1 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | HOLOBIOME, INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240165169-A1 | Pharmaceutical Combinations for Treating Cancer | T3 PHARMACEUTICALS AG (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20240165265-A1 | Pharmaceutical Combinations for Treating Cancer | T3 PHARMACEUTICALS AG (CH) | 2024-05-23 | — | — | US | disclosed |
| CN-118006531-A | Attenuated bacteria-based protein delivery | 巴塞尔大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-110325545-B | Attenuated bacteria-based protein delivery | 巴塞尔大学 | 2024-02-09 | — | — | CN | disclosed |
| EP-4313310-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 Pharmaceuticals AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| EP-4314036-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | T3 Pharmaceuticals AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-10563174-B2 | Proteins increasing pancreatic beta cell number and methods of use | UNIVERSITY OF OREGON (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170292115-A1 | PROTEINS INCREASING PANCREATIC BETA CELL NUMBER AND METHODS OF USE | UNIVERSITY OF OREGON (US) | 2017-10-12 | — | — | US | disclosed |
| US-7869957-B2 | Methods and systems to identify operational reaction pathways | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-11 | — | — | US | disclosed |
| US-7635572-B2 | Methods for conducting assays for enzyme activity on protein microarrays | Life Technologies Corporation (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2098597-A1 | Method for manufacturing L-amino acids using improved strains of the enterobacteriaceae family | Evonik Degussa GmbH (DE) | 2009-09-09 | — | — | EP | disclosed |
| EP-1642109-A4 | METHODS FOR CONDUCTING ASSAYS FOR ENZYME ACTIVITY ON PROTEIN MICROARRAYS | PROTOMETRIX INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1642109-A2 | METHODS FOR CONDUCTING ASSAYS FOR ENZYME ACTIVITY ON PROTEIN MICROARRAYS | Protometrix, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050118665-A1 | Methods for conducting assays for enzyme activity on protein microarrays | PROTOMETRIX, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005003721-A2 | ENZYME ACTIVITY ASSAYS ON PROTEIN MICROARRAYS | PROTOMETRIX, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262254-A1 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | TPH1, TPH2, HTR1A | ATIC 2448/4885FBP1 1850/4885KDM4E 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.